Delix raises $100 million with J&J backing to advance psychedelic-inspired depression drug into Phase II
Summary
Delix Therapeutics raised an oversubscribed $100 million Series C to advance zalsupindole into Phase II and fund its broader pipeline. Johnson & Johnson's venture arm and SV Health Investors' Dementia Discovery Fund co-led the round. Inspired by 5‑MeO‑DMT, zalsupindole is designed to promote synaptic repair without hallucinations. A small, uncontrolled Phase Ib study of 18 patients found a roughly 50% mean reduction in depression scores after one week, with effects lasting through day 36. A placebo-controlled Phase II trial in major depressive disorder is expected to begin in the first half of 2027. Controlled studies must still establish efficacy and durability.